MedTrace Logo

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-14

No results posted yet for this study

Summary

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Conditions

  • B Cell Lymphoma
  • NHL, Adult
  • Mantle Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • DLBCL - Diffuse Large B Cell Lymphoma
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements
  • High-grade B-cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • T-Cell/Histiocyte Rich Lymphoma
  • Non-hodgkin Lymphoma,B Cell
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Epstein-Barr Virus Positive DLBCL, Nos
  • Follicular Lymphoma Grade 3B
  • DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Follicular Lymphoma Grade 3
  • Marginal Zone Splenic Lymphoma
  • DLBCL
  • Waldenstrom Macroglobulinemia
  • Waldenstrom Macroglobulinaemia

Interventions

BIOLOGICAL

SynKIR-310

Autologous T Cells transduced with CD19 KIR-CAR

Sponsors & Collaborators

  • Verismo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Laura A Johnson, PhD · Verismo Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2028-09-30
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06544265 on ClinicalTrials.gov